Carriers and brokers selling Side-A directors and officers liability insurance coverage by delivering warnings about the increasing severity of shareholder derivative lawsuits may be overstating the trend, according to one attorney involved in a major case.
"I don't think it's all of a sudden going to open the floodgates, said Mark Lebovitch, a plaintiffs' lawyer for Bernstein Litowitz Berger & Grossmann LLP in New York, referring to a shareholder derivative action brought by Amalgamated Bank and other shareholders late last year against directors and officers of New York-based Pfizer, a large pharmaceutical company.
The stakes in the case are potentially high, with the derivative lawsuit filing coming in the wake of a $2.3 billion settlement with the government arising from what the U.S. Department of Justice found to be fraudulent and criminal promotional activities used to sell 13 of Pfizer's most important drugs.
Want to continue reading?
Become a Free PropertyCasualty360 Digital Reader
Your access to unlimited PropertyCasualty360 content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- All PropertyCasualty360.com news coverage, best practices, and in-depth analysis.
- Educational webcasts, resources from industry leaders, and informative newsletters.
- Other award-winning websites including BenefitsPRO.com and ThinkAdvisor.com.
Already have an account? Sign In
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
